Key takeaways
Based on studies, most people lose about 2% of their body weight in the first month of taking Wegovy.
Wegovy starts working within 1–3 days of your first shot or within 1 hour of your first oral dose, although noticeable weight loss takes longer.
Many people notice weight loss results from Wegovy within 5–12 weeks after starting treatment.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Based on studies, most people lose about 2% of their body weight in the first month of taking Wegovy.
Wegovy starts working within 1–3 days of your first shot or within 1 hour of your first oral dose, although noticeable weight loss takes longer.
Many people notice weight loss results from Wegovy within 5–12 weeks after starting treatment.
Wegovy is a once-weekly weight loss medication that many people turn to when their current eating habits and exercise routine aren’t enough. But how long does it take Wegovy to work for weight loss? Semaglutide, the active ingredient in Wegovy, begins to affect your body within days. It may take several weeks, however, to notice a change in body weight.
On average, people taking injectable or oral Wegovy lose about 2% of their body weight in the first month and 6% in the first three months.
How long does it take for Wegovy to work for weight loss?
In one study, people on 1.7 mg and 2.4 mg doses of injectable Wegovy lost an average of 6% of their body weight after three months and 11% after six months. Other research has found that people notice about 2% weight loss in the first month. The weight loss results are similar for people taking the Wegovy pill.
Wegovy weight loss timeline
Timeframe | Average weight loss |
|---|---|
4 weeks (1 month) | ~2% of starting body weight |
8 weeks (2 months) | ~4% of starting body weight |
12 weeks (3 months) | ~6% of starting body weight |
16 weeks (4 months) | ~8% of starting body weight |
24 weeks (6 months) | ~10-11% of starting body weight |
40 weeks (~9 months) | ~13-14% of starting body weight |
52 weeks (12 months) | ~14-16% of starting body weight |
At what dose does Wegovy start working?
Wegovy’s active ingredient semaglutide starts working within days (injection) or hours (pill) of the first dose, but it takes longer to notice weight loss. Wegovy is designed to deliver meaningful weight loss results once you reach the higher maintenance dosage of 1.7 mg or 2.4 mg per week (for the injection) or 25 mg daily (for the pill). That typically happens around four months after starting treatment.
Wegovy treatment starts at a low dose (0.25 mg for the injection and 1.5 mg for the pill) to minimize digestive side effects and help your body adjust. Your dose then gradually increases over time.
The effects of Wegovy are dose-dependent, meaning people on higher doses tend to experience more weight loss than those on lower doses. A study reviewing medical records from a weight management clinic found that, on average:
People who used higher doses of injectable Wegovy (1.7 mg or 2.4 mg) lost about 7% of their body weight after three months and 12% after six months.
People who used lower doses (0.25 mg, 0.5 mg, or 1 mg) also lost weight, though not as much — about 5% at three months and 9% at six months.
How quickly can you lose weight on Wegovy?
The answer varies from person to person. How quickly you lose weight on Wegovy depends on factors like your dosage and lifestyle.
Here’s an approximate Wegovy weight loss timeline for people taking 2.4 mg (the highest maintenance dose of injectable Wegovy) or 25 mg (the maintenance dose for the oral Wegovy pill), based on research. On average, people taking semaglutide in clinical studies lost about 13.6%–15% of their body weight in less than a year and a half.
Example Wegovy weight loss timeline
Timeline | Wegovy injection | Wegovy pill |
|---|---|---|
Month 1 | 2% of body weight lost | 2% of body weight lost |
Month 2 | 4% of body weight lost | 4% of body weight lost |
Month 3 | 6% of body weight lost | 6% of body weight lost |
Month 4 | 8% of body weight lost | 8% of body weight lost |
Month 6 | 11% of body weight lost | 10% of body weight lost |
Month 9 | 14% of body weight lost | 13% of body weight lost |
Month 12 | 16% of body weight lost | 14% of body weight lost |
Wegovy dosage
Your Wegovy dosage may affect how much weight you lose or how quickly you lose it. One study found that people on higher doses of injectable Wegovy lost more weight than those prescribed lower doses. Specifically, people who received 1.7 mg or 2.4 mg of Wegovy per week lost an average of about 7% of their body weight in three months. Those on doses of 0.25 mg, 0.5 mg, or 1 mg lost an average of 5.1% in the same period.
The Wegovy pill also produces slightly less weight loss than the Wegovy injection, even at its maximum maintenance dosage. After 64 weeks on 25 mg of oral Wegovy, people lost an average of 13.6% of their starting body weight. After 68 weeks on injectable Wegovy, people lost an average of 14.9% of their starting body weight.
Average three-month weight loss by Wegovy dosage
Dosage | Amount of weight loss |
|---|---|
Maintenance doses of Wegovy injection (1.7 mg or 2.4 mg) | 6.9% |
Maintenance dose of Wegovy pill (25 mg) | 6% |
Lower doses of Wegovy injection (0.25 mg, 0.5 mg, 1 mg) | 5.1% |
What happens if you miss a dose of Wegovy?
Missing a dose of any medication means that your body is temporarily missing out on the drug’s benefits — and that’s true for Wegovy, too. If you skip a dose, you may reduce Wegovy’s effectiveness and increase the risk of side effects when you resume treatment.
Injectable Wegovy is taken once a week, on the same day each week, while oral Wegovy is taken daily in the morning. People who take their medication consistently and follow their prescription are more likely to experience weight loss results similar to those in clinical studies.
Other factors that can affect how long Wegovy takes to work
The rate of weight loss with Wegovy varies from person to person. Underlying medical conditions, eating habits, and exercise can affect how quickly you lose weight.
Health conditions
Sometimes, underlying health conditions like Cushing’s syndrome or hypothyroidism can contribute to weight gain or obesity. If you have a health condition that makes it harder to maintain a healthy weight, it may also affect how quickly you’re able to lose weight on Wegovy. It’s also possible that Wegovy will offer additional benefits related to your health condition — which is one reason some people take Wegovy for PCOS.
Type 2 diabetes can also make it harder to lose weight quickly on GLP-1 medications like Wegovy. One clinical study found that people taking injectable semaglutide with type 2 diabetes lost about one-third less body weight than those without the condition.
Diet and exercise
Wegovy isn’t a magic bullet for weight loss. The drug’s prescribing information states that Wegovy should be combined with a reduced-calorie eating plan and increased physical activity.
Following a Wegovy eating plan rich in fruits and vegetables, lean proteins, whole grains, and healthy fats may help maximize your weight loss results — including how long it takes to see them. The same goes for physical activity: building and sticking to an exercise routine for weight loss can support, rather than slow, the drug’s weight reduction effects.
Other lifestyle factors
Lifestyle factors like poor sleep, chronic stress, and alcohol consumption can also make weight loss more difficult, slowing your Wegovy weight loss results.
For example, ongoing sleep deprivation may increase the likelihood of late-night snacking. Getting 7–9 hours of sleep per night may help curb extra calorie intake throughout the day.
Stress may also increase cravings and appetite, and research has linked alcohol consumption to weight gain.
The main thing to remember is that your rate of weight loss on Wegovy can be affected by many factors — from a less nutritious eating plan to chronic stress.
Where to get Wegovy for weight loss quickly
You can get access to Wegovy for weight loss through the Ro Body program. Here’s what the membership includes:
Ongoing clinical care from a Ro-affiliated provider, including monthly check-ins and unlimited, free messaging
Prescription for GLP-1 medications, such as Wegovy, Zepbound, or Ozempic (if eligible)
1:1 health coaching for behavior change support and accountability
Insurance concierge to help verify coverage, manage prior authorizations, and lower out-of-pocket costs
Side effect support, including prescriptions for anti-nausea medications if needed
App-based tools for keeping track of your doses, weight changes, and treatment updates
Ro’s weight loss program is designed to make clinical weight loss care more accessible, flexible, and affordable. The membership starts at $45 for the first month, then $145 per month after that. The price of GLP-1 medications isn’t included and will vary depending on your insurance and treatment plan.
For those paying out of pocket, Ro offers cash-pay options that are often significantly less than retail prices, through integrations with LillyDirect and NovoCare.
How does Wegovy compare to other weight loss medications?
Among weight loss medications, Wegovy is one of the most effective options currently available. The only medication that currently produces more weight loss than Wegovy is Zepbound.
Average three-month weight loss by medication
Wegovy | 6% |
Zepbound | 8% |
Saxenda | 2.5% |
Qsymia | 3%–5% |
Contrave | 4% |
Xenical | 3.8% |
Wegovy vs. Zepbound
Zepbound (tirzepatide) is another once-weekly injectable weight loss medication available through the Ro Body program. Zepbound produces more weight loss than Wegovy.
In 12 weeks, people taking Wegovy lose an average of 6% of their starting body weight.
In 12 weeks, people taking Zepbound lose an average of 8% of their starting body weight.
Wegovy vs. Saxenda
Saxenda (liraglutide) is a daily injectable weight loss medication available through the Ro Body program. Saxenda produces less weight loss than Wegovy. In a study comparing the two directly, people lost twice as much weight on Wegovy as on Saxenda in one year.
In 12 weeks, people taking Wegovy lose an average of 6% of their starting body weight.
In 12 weeks, people taking Saxenda lose about 2% of their starting body weight.
Wegovy vs. Qsymia
Qsymia (phentermine-topiramate) is a daily weight loss pill approved by the US Food and Drug Administration (FDA) for long-term weight loss. It's available by prescription through a licensed healthcare provider. Qsymia produces less weight loss than Wegovy.
In 12 weeks, people taking Wegovy lose an average of 6% of their starting body weight.
In 12 weeks, people taking Qsymia may lose 3%–5% of their starting body weight.
Wegovy vs. Contrave
Contrave (naltrexone/bupropion) is a twice-daily weight loss pill available by prescription through a licensed healthcare provider. Contrave produces less weight loss than Wegovy over three months.
In 12 weeks, people taking Wegovy lose an average of 6% of their starting body weight.
In 12 weeks, people taking Contrave lose an average of 4% of their starting body weight.
Wegovy vs. Xenical
Xenical (orlistat) is a thrice-daily weight loss pill available by prescription through a licensed healthcare provider. It's also available over the counter in a lower-strength formulation called Alli. Xenical produces less weight loss than Wegovy.
In 12 weeks, people taking Wegovy lose an average of 6% of their starting body weight.
In 12 weeks, people taking Xenical lose an average of 3.8% of their starting body weight.
Bottom line
Whether you're considering Wegovy or have just started treatment, it's natural to ask: when does Wegovy start working? The answer is very soon after the first dose. How long before Wegovy starts working for weight loss depends on factors like your dosage, underlying health conditions, and whether you're following a healthy eating plan and exercise routine.
Here are five takeaways to know:
Wegovy starts working after the first shot or oral dose. It only takes 1–3 days (injection) or 1 hour (pill) before Wegovy reaches peak concentration in your body after each dose.
Most people lose weight on Wegovy within three months. People taking Wegovy lost about 2% of their body weight after one month and 6% after three months.
Other factors affect weight loss pace. Dosage, whether you miss a dose, other health conditions, and lifestyle factors can all affect weight loss on Wegovy.
Only one weight loss medication is more effective than Wegovy: Zepbound. In three months, it produces an average 8% weight loss vs. 6% with Wegovy.
If you’re not getting results from Wegovy, talk to your prescriber. A healthcare provider can increase your dosage (if needed) or recommend other next steps.
Frequently asked questions (FAQs)
How much weight can you lose on Wegovy?
How much weight you lose on Wegovy may depend on your starting weight, how long you stay on the medication, and the lifestyle changes you make. In clinical studies, participants lost 15% of their body weight after 16 months on injectable Wegovy and 13.6% after 15 months on the Wegovy pill.
How long should you take Wegovy for weight loss?
There is no set timeline for how long to take Wegovy for weight loss. Most people take it for at least three months to see if it works for them. After that, Wegovy may be continued long term to support weight maintenance. It’s worth knowing that stopping Wegovy may lead to significant weight regain. Talk to your healthcare provider to determine the right timeline for you.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Saxenda Important Safety Information: Read more about serious warnings and safety info.
References
Ahn, S. M., Kim, H., Ji, E., et al. (2013). The effect of orlistat on weight reduction in obese and overweight Korean patients. Archives of Pharmacal Research, 37(4), 512–519. doi: 10.1007/s12272-013-0201-8. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23839080/
Centers for Disease Control and Prevention (CDC). (2025). Steps for losing weight. Retrieved from https://www.cdc.gov/healthy-weight-growth/losing-weight/
DailyMed. (2025). Qsymia- phentermine and topiramate capsule, extended release. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9
Gasoyan, H., Pfoh, E. R., Schulte, R., et al. (2024). One-Year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Network Open, 7(9), e2433326. doi: 10.1001/jamanetworkopen.2024.33326. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11400221/
Geiker, N. R. W., Astrup, A., Hjorth, M. F., et al. (2018). Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity, 19(1), 81–97. https://doi.org/10.1111/obr.12603. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28849612/
Ghusn, W., De la Rosa, A., Sacoto, D., et al. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, 5(9), e2231982. doi: 10.1001/jamanetworkopen.2022.31982. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/
Hall, K. D. & Kahan, S. (2018). Maintenance of Lost Weight and Long-Term Management of Obesity. The Medical Clinics of North America, 102(1), 183–197. https://doi.org/10.1016/j.mcna.2017.08.012. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5764193/
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. doi: 10.1056/nejmoa2206038. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2206038
Jensterle, M., Rizzo, M., Haluzík, M., et al. (2022). Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy, 39(6), 2452–2467. doi: 10.1007/s12325-022-02153-x. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9063254/
Johnson, D. B. & Quick, J. (2023). Topiramate and phentermine. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482165/
McElroy, S. L., Guerdjikova, A. I., Kim, D. D., et al. (2013). Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder. The Primary Care Companion for CNS Disorders, 15(3). doi: 10.4088/pcc.12m01494. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3795584/
National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Factors affecting weight health. Retrieved from https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/factors-affecting-weight-health
Papatriantafyllou, E., Efthymiou, D., Zoumbaneas, E., et al. (2022). Sleep Deprivation: Effects on Weight Loss and Weight Loss Maintenance. Nutrients, 14(8), 1549. https://doi.org/10.3390/nu14081549. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9031614/
U.S. Food & Drug Administration (FDA). (2025). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use; Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. doi:10.1056/nejmoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969?url_ver=Z39.88-2003
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183/
Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism, 24(8), 1553–1564. doi: 10.1111/dom.14725. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/














